Hormonal
Obesity and metabolic disease are driven by a misalignment between behaviors (feeding/fasting rhythms, physical activity) and tissue functions (organ clocks), regulated by circadian molecular clocks in the brain and periphery.
Your body's organs operate on a 24-hour schedule. Try to align your eating and sleeping times with your natural circadian rhythm. Eating large meals late at night or irregularly can disrupt the internal clocks in your liver, muscle, and fat, leading to metabolic issues. Consistent meal times and adequate sleep support better metabolic health.
Perturbations to this system – promoted by the obesogenic environment – ultimately result in misalignment between behaviors (food intake and physical activity) and tissue functions (e.g., WAT lipid storage/release, liver macronutrient supply, muscle macronutrient uptake, pancreatic hormone release), which manifest in metabolic disorders.
Why this rating
The paper synthesizes extensive preclinical and clinical evidence linking circadian rhythms to metabolism, citing multiple studies on clock genes and metabolic outcomes.
Source
Brain–body communication in metabolic control
Alessandro Furlan et al. · Trends in Endocrinology and Metabolism · 2023
DOI 10.1016/j.tem.2023.08.014
More from this paper
- Physical activity improves metabolic health and reduces blood glucose levels independently of weight loss and insulin signaling pathways.Good
- Vagus nerve stimulation (VNS) and GLP-1 analogs are emerging therapeutic tools that harness brain-body communication to treat obesity and diabetes, though more invasive and long-lasting approaches are needed.Good
- Brown adipose tissue (BAT) activation and the 'browning' of white adipose tissue (WAT) represent a potential therapeutic avenue for increasing energy expenditure and reducing body weight, although its clinical relevance in humans remains debated.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →